En Es
Categories

Industry News


Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
Gold member
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
24 Nov 2021
Euromedlab Congress 2021 Postponed as Fourth COVID-19 Wave Hits Germany
The XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021) to be held as an in-presence meeting between 28th of November and 2nd of December in Germany has been postponed as the country has been hit very hard by a fourth wave of COVID-19.
Read More
19 Nov 2021
44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience
The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close.
Read More
16 Nov 2021
Deborah Bowen (USA) Takes Up Position of IHF President for 2021-2023
Deborah Bowen has taken up the position of President of the International Hospital Federation (IHF; Geneva, Switzerland) following her election in 2019 and a two-year term as President Designate.
Read More
16 Nov 2021
IHF and Deloitte Collaborate to Launch Special Interest Group on Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) will collaborate with Deloitte (London, UK) to launch a special interest group (SIG) centered around leadership for sustainability.
Read More
16 Nov 2021
International Hospital Federation (IHF) Announces Winners of IHF Awards 2021
The International Hospital Federation (IHF; Geneva, Switzerland) announced the winners of the IHF Awards 2021 as part of a special ceremony at the 44th World Hospital Congress (WHC) held in Barcelona, Spain.
Read More
13 Nov 2021
GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health
General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.
Read More
11 Nov 2021
Blood Borne Testing Market to Witness Exponential Growth Due to Rising Incidence of Bacterial Infections
The global blood borne testing market is projected to record an exponential CAGR of over 7-8% during 2021-2031, driven by increasing bacterial infection and growing adoption of point of care devices, aided further by technological advancement in devices for blood borne pathogens. These are the latest findings of Fact.MR (Dublin, Ireland), a market research firm.
Read More
10 Nov 2021
AI in Radiology Market Driven by Growing Adoption of Machine Learning Tools in Broad Spectrum of Imaging Applications
The use of AI algorithms in medical image analysis field has made astounding progress. Particularly deep learning has made incessant inroads in radiology practice. The major consumer proposition for companies in the AI in radiology market stems from the exceptional capabilities of AI tools in recognizing complex patterns in the imaging data. These are the latest findings of Transparency Market Research (Albany NY, USA).
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions